Skip to content


  • Review
  • Open Access

Dissecting cellular senescence and SASP in Drosophila

Inflammation and Regeneration201636:25

  • Received: 17 September 2016
  • Accepted: 15 November 2016
  • Published:


Cellular senescence can act as both tumor suppressor and tumor promoter depending on the cellular contexts. On one hand, premature senescence has been considered as an innate host defense mechanism against carcinogenesis in mammals. In response to various stresses including oxidative stress, DNA damage, and oncogenic stress, suffered cells undergo irreversible cell cycle arrest, leading to tumor suppression. On the other hand, recent studies in mammalian systems have revealed that senescent cells can drive oncogenesis by secreting diverse proteins such as inflammatory cytokines, matrix remodeling factors, and growth factors, the phenomenon called senescence-associated secretory phenotype (SASP). However, the mechanisms by which these contradictory effects regulate tumor growth and metastasis in vivo have been elusive. Here, we review the recent discovery of cellular senescence in Drosophila and the mechanisms underlying senescence-mediated tumor regulation dissected by Drosophila genetics.


  • Cell Cycle Arrest
  • Cellular Senescence
  • Senescent Cell
  • Hippo Pathway
  • Hippo Signaling


Cellular senescence has been considered to be a major defense mechanism against carcinogenesis through the induction of stable cell cycle arrest [16]. Aberrant oncogene activation such as Ras activation causes various stresses including oxidative stress and DNA damage, thereby leading to the induction of premature senescence independently of telomere emersion [2, 3, 518]. This oncogene-induced senescence (OIS) can block malignant progression of precancerous lesions [57, 16]. However, recent studies have indicated that senescent cells can also contribute to tumor progression via the release of secretory components such as inflammatory cytokines, matrix remodeling factors, and growth factors, which is called the senescence-associated secretory phenotype (SASP) [1922]. Thus, cellular senescence has not only negative effects but also positive effects on tumor development. Therefore, elucidation of how senescent cells drive both tumor suppression and tumor progression through cell–cell communications in vivo is essential if taking into account cellular senescence as a therapeutic target for cancer.

The genetic mosaic technique available in Drosophila is a powerful tool to study cell–cell communications in vivo [23, 24]. This technique allows us to analyze in vivo interactions between senescent cells and surrounding cells during tumor progression. In this review, we describe the recent identification of cellular senescence in Drosophila, as well as the recent advances in our understanding of the mechanisms by which senescent cells drive tumor progression via SASP in Drosophila.

Cellular senescence and SASP in Drosophila

Since the first discovery by Hayflick and Moorhead in 1961 [25], cellular senescence has been widely studied in mammalian cells. Cellular senescence is known as a stepwise process from early senescence to full senescence [2630]. In an early senescence state, senescent cells exhibit senescence-associated β-galactosidase (SA-β-gal) activity [31, 32], elevated expression of cyclin-dependent kinase (CDK) inhibitors such as p16 [12, 33, 34] and p21 [12, 3537], reversible cell cycle arrest, senescence-associated heterochromatic foci (SAHF) [3841], and cellular hypertrophy [31]. When matured to a full senescence state, senescent cells exhibit additional phenotypes including irreversible cell cycle arrest and SASP. Despite the extensive studies of cellular senescence in vertebrate models, there has been no evidence that cellular senescence also occurs in invertebrates.

Using Drosophila genetics, it has recently been shown that the state of full senescence can be induced by simultaneous activation of the Ras oncogene and mitochondrial dysfunction in Drosophila imaginal epithelium [42, 43]. Clones of cells with Ras activation and dysfunction of the mitochondrial electron transport chain (RasV12/mito −/− clones), both of which are frequently observed in various types of human cancers [4448], show elevated SA-β-gal activity, cell cycle arrest accompanied with upregulation of the Cdk inhibitor Dacapo (a Drosophila p21/p27 homologue), SAHF, and cellular hypertrophy [42]. In addition, RasV12/mito −/− cells present SASP, as these cells excessively secrete the inflammatory cytokine Unpaired (Upd; a Drosophila interleukin 6 (IL-6) homologue [49]) and matrix metalloprotease 1 (Mmp1; the Drosophila secreted Mmp [50]), thereby causing non-autonomous overgrowth of neighboring cells (Fig. 1) [42, 43]. IL-6 and Mmp are known as SASP factors in mammals [21]. Intriguingly, clones of cells with Ras activation alone (RasV12 clones) show elevated SA-β-gal activity, Dacapo upregulation, SAHF, and cellular hypertrophy but not cell cycle arrest and SASP [42]. Thus, Ras activation alone is insufficient for the induction of full senescence in Drosophila imaginal epithelium. Accordingly, mitochondrial dysfunction seems to be crucial for the acceleration of Ras-mediated OIS. These findings indicate that cellular senescence and SASP are evolutionally conserved in invertebrates and that studies in Drosophila could provide novel mechanistic insights into these phenomena.
Fig. 1
Fig. 1

Senescent RasV12/mito −/− cells trigger non-autonomous overgrowth of surrounding cells via SASP in Drosophila. a RasV12/mito −/− cells induce non-autonomous overgrowth of surrounding normal cells. b RasV12/mito −/− cells induce non-autonomous overgrowth and invasion of surrounding RasV12 cells

Regulation of cell cycle arrest in Drosophila senescent cells

DNA damage is known to be the major cause of cellular senescence [1, 51]. Studies in mammalian systems have indicated that Ras activation elicits DNA damage mainly through DNA hyper-replication [3, 10] and production of reactive oxygen species (ROS) [13, 5155]. It has also been well established that the ROS-induced DNA damage triggers cellular senescence. Intriguingly, in Drosophila imaginal epithelium, Ras activation and dysfunction of the mitochondrial respiratory chain synergize in inducing ROS production and DNA damage [42, 43]. RasV12/mito −/− cells show much larger amount of ROS production and DNA damage than RasV12 cells or mito −/− cells. A recent study in human cell cultures has indicated that RasV12 cells show elevated mitochondrial respiration via enhanced conversion of pyruvate to acetyl-CoA that is the origin of mitochondrial tricarboxylic acid (TCA) cycle [56]. Therefore, when the mitochondrial electron transport is downregulated in RasV12 cells, large amounts of metabolic intermediates in mitochondrial respiration may be accumulated in mitochondria, which could affect ROS production.

It has been shown in mammals that DNA damage triggers cell cycle arrest and thereby induces cellular senescence [1, 51]. Upon DNA damage, p53 and p16 are upregulated [5761] and thereby activating the p53/p21/Rb pathway [35, 36, 62, 63] and the p16/Rb pathway [62, 64]. DNA damage stabilizes p53 protein by repressing the ubiquitin ligase Mdm2 [5759]. p53 directly activates transcription of p21 [35]. Both p21 and p16 positively regulate the function of retinoblastoma 1 (Rb1), a cell cycle keeper, by repressing the activities of CDKs. p21 represses the activity of the Cyclin E-CDK2 complex, while p16 represses the activity of the Cyclin D-CDK4-CDK6 complex, leading to the induction of cell cycle arrest. Intriguingly, the mechanism regulating expression of Cdk inhibitors during cellular senescence in Drosophila seems to be distinct from mammals in three ways. First, DNA damage is not involved in stabilization of Drosophila p53 (dp53) protein [42, 65]. Drosophila RasV12/mito −/− cells, in which huge amount of ROS production and DNA damage occur, present larger elevation of dp53 than RasV12 cells or mito −/− cells [42]. Nonetheless, this dp53 elevation is not blocked by suppression of ROS production, suggesting that dp53 protein level is not affected by oxidative DNA damage. Indeed, it has been reported that ionizing radiation (IR)-induced DNA damage does not change dp53 protein level, but it activates dp53 function via Loki (a Chk2 homologue)-dependent phosphorylation [65]. Similarly to mammalian Chk2, Loki acts as a kinase downstream of DNA damage-responsive kinases Tefu (an ATM homologue) and Mei-41 (an ATR homologue) [66, 67]. Thus, an alternative mechanism, not DNA damage, may stabilize dp53 protein, while DNA damage activates dp53 function. Second, dp53 does not regulate expression of Drosophila p21/p27, Dacapo [65, 68]. Loss of the dp53 gene in RasV12/mito −/− cells does not block elevation of Dacapo (our unpublished data), which is consistent with previous reports indicating that dp53 does not participate in the regulation of Dacapo expression [65, 68]. Meanwhile, it has been shown that the expression level of Dacapo in RasV12 cells is comparable with that in RasV12/mito −/− cells but is much higher than that in mito −/− cells [42]. These observations indicate that Dacapo expression is dependent on Ras function but not dp53 function. In fact, previous studies have indicated that dp53 has a much closer relationship with apoptosis than cell cycle arrest [65, 6972]. Finally, p16, another CDK inhibitor crucial for the induction of cellular senescence in mammals, is not conserved in Drosophila. Collectively, RasV12-induced Dacapo elevation seems to be the central event triggering cell cycle arrest during cellular senescence in Drosophila.

The mechanism by which p53 regulates cyclin E protein stability, however, is conserved in Drosophila. It has been reported that dp53 induces ubiquitin-mediated proteolysis of cyclin E by activating gene expression of an E3 ubiquitin ligase Archipelago (Ago; a Fbxw7 homologue) [7375]. It is known that gene transcription of mammalian Fbxw7 is positively regulated by p53 and that Fbxw7 leads to degradation of cyclin E through its ubiquitin ligase activity [7678]. Together, these observations suggest that RasV12-induced Dacapo upregulation and dp53-induced cyclin E degradation may cooperatively drive rigid cell cycle arrest in RasV12/mito −/− cells in Drosophila.

Roles of JNK and Hippo signaling in SASP

The c-Jun N-terminal kinase (JNK) pathway is a kinase cascade that mediates stress signaling such as oxidative stress and DNA damage [7983]. Drosophila RasV12/mito −/− senescent cells show much higher Drosophila JNK (dJNK; a JNK 1/2/3 homologue) activity than RasV12 cells or mito −/− cells, and this dJNK activation is blocked by ROS inhibition [43]. Intriguingly, prominent activation of dJNK in RasV12/mito −/− cells is achieved by cell cycle arrest [42]. Cyclin E overexpression in RasV12/mito −/− cells inhibits dJNK activation without affecting ROS production [42]. In addition, Ras activation, which causes a weak induction of ROS, and loss of cyclin E synergistically trigger excessive activation of dJNK [42, 43]. Ras activation alone slightly increases dJNK activity, while loss of cyclin E alone is insufficient for the induction of dJNK activation. These observations suggest that cell cycle arrest can amplify dJNK activity without changing ROS level. Furthermore, dJNK activation can induce cell cycle arrest [42], which is consistent with a previous report showing that JNK1 stabilizes p21 protein via phosphorylation in a human colon cancer cell line [84]. Taken together, these data suggest the existence of a positive feedback loop between dJNK signaling and cell cycle arrest in RasV12/mito −/− cells, and this loop and oxidative DNA damage may act synergistically to induce excessive activation of dJNK.

Previous reports have suggested a close link between JNK signaling and SASP. SASP is considered to be regulated by NF-κB signaling and epigenetic mechanisms in mammals. NF-κB signaling positively regulates SASP during cellular senescence downstream of Ras signaling [8589]. Epigenetic mechanisms, such as chromatin remodeling, histone modification, and microRNA, also affect SASP [30, 9094]. On the other hand, JNK has been shown to regulate expression of SASP factors including matrix remodeling factors and inflammatory cytokines both in mammals and Drosophila. As for matrix remodeling factors, mammalian JNK induces expression of Mmps via transcription factor activator protein-1 (AP-1) family [95100], while dJNK induces Mmp1 elevation via Drosophila Fos (dFos), an AP-1 family member [101103]. As for inflammatory cytokines, mammalian JNK induces elevation of IL-6 [104106], IL-8 [107, 108], and monocyte chemoattractant protein-1 (MCP-1) [109111], while dJNK induces elevation of Upd (an IL-6 homologue) [101, 112, 113]. In Drosophila RasV12/mito −/− cells, dJNK upregulates Upd via inactivation of the Hippo pathway [42, 43]. The Hippo pathway is an evolutionally conserved tumor suppressor signaling that regulates cell proliferation and cell death [114, 115]. In mammals, Mst1/2 and Lats1/2, the core components of the Hippo pathway, repress the Hippo effectors Yap1/2 and Taz via phosphorylation [114, 116120]. Similarly, in Drosophila, Hippo (a Mst1/2 homologue) and Warts (a Lats1/2 homologue) inactivate Yorkie (Yki; a Yap1 homologue) via phosphorylation [114, 116, 120124]. Recent studies have reported that the Hippo pathway negatively regulates expression of SASP factors including IL-6 in mammals [125128], similarly to Drosophila cells [129132]. Marked upregulation of Upd in Drosophila RasV12/mito −/− cells is blocked by expression of a dominant negative form of dJNK, cyclin E, Warts, or RNAi-mediated knockdown of Yki [42, 43]. Furthermore, it has been shown that dJNK signaling and Ras signaling cooperatively inactivate the Hippo pathway, thereby inducing SASP. Recent studies in Drosophila and human cell cultures have shown that JNK signaling and Ras signaling act synergistically to inhibit the Hippo pathway via Ajuba LIM protein (Jub)/Ajuba family proteins, which are known as Warts/LATS inhibitors [133138]. Thus, Jub/Ajuba family proteins may also act as key regulators of SASP during cellular senescence. These findings indicate the importance of JNK signaling in the induction of SASP.

Senescence or apoptosis?

Apart from cellular senescence, apoptosis also acts as a major defense mechanism against tumorigenesis [139]. Apoptosis is an active cell death program executed by killer proteases called caspases [140142]. Are there any functional relationships between cellular senescence and apoptosis? Studies in Drosophila have indicated that Ras signaling negatively regulates the function of the pro-apoptotic protein head involution defective (Hid) both transcriptionally and post-transcriptionally, thereby suppressing apoptosis [143, 144]. Interestingly, senescent RasV12/mito −/− cells seem to exhibit apoptosis resistance [42, 43]. On the other hand, in mammals, Ras signaling not only induces cellular senescence but also suppresses apoptosis [145, 146]. Interestingly, it has also been shown in mammals that senescent cells have the resistance to apoptosis [147150]. Conversely, apoptosis inhibition by the pan-caspase inhibitor accelerates the anticancer agent-induced senescence in human culture cells, suggesting that apoptotic signaling antagonizes cellular senescence [151]. Therefore, two major tumor-suppressive machineries, cellular senescence and apoptosis, seem to counteract each other. Future studies on common signaling involved in both cellular senescence and apoptosis would increase our understanding of how these machineries cooperatively regulate tumorigenesis.


Recent studies in Drosophila have revealed that cellular senescence and SASP exist in invertebrates and that Ras activation and mitochondrial dysfunction synergistically drive cellular senescence and SASP via complex mechanisms mediated by JNK and Hippo signaling (Fig. 2). These findings have opened a new direction of the research field of cellular senescence. Future studies taking advantages of the powerful genetics of Drosophila would provide novel insights into cellular senescence and SASP, as well as new therapeutic strategies against cancers.
Fig. 2
Fig. 2

Scheme of the underlying mechanisms driving cellular senescence and SASP in Drosophila RasV12/mito −/− cells





Activator protein-1


Cyclin-dependent kinase


Drosophila Fos


Drosophila JNK


Drosophila p53


Head involution defective


Interleukin 6


Ionizing radiation


c-Jun N-terminal kinase


Matrix metalloprotease


Oncogene-induced senescence


Retinoblastoma 1


Reactive oxygen species


Senescence-associated heterochromatic foci


Senescence-associated secretory phenotype


Senescence-associated β-galactosidase


Tricarboxylic acid







Not applicable.


The work in the Igaki laboratory was supported in part by Grant-in-Aid for Scientific Research (A) (16H02505), Grant-in-Aid for Scientific Research on Innovative Areas (26114002), Grant-in-Aid for Challenging Exploratory Research (16K14606), the Takeda Science Foundation, and the Japan Science and Technology Agency.

Availability of data and materials

Not applicable.

Authors’ contributions

Both authors wrote this paper. Both authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Laboratory of Genetics, Graduate School of Biostudies, Kyoto University, Yoshida-Konoecho-cho, Sakyo-ku, Kyoto, 606-8501, Japan


  1. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001;11(11):S27–31.PubMedView ArticleGoogle Scholar
  2. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864–70. 861.PubMedView ArticleGoogle Scholar
  3. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444(7119):633–7.PubMedView ArticleGoogle Scholar
  4. Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A, Arkan MC, Kirchner T, Greten FR. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell. 2010;18(2):135–46.PubMedView ArticleGoogle Scholar
  5. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt CA. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436(7051):660–5.PubMedView ArticleGoogle Scholar
  6. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725–30. 722.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720–4.PubMedView ArticleGoogle Scholar
  8. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene. 2008;27(20):2801–9. 2804.PubMedView ArticleGoogle Scholar
  9. Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic Ras-induced senescence. Oncogene. 2004;23(57):9238–46.PubMedGoogle Scholar
  10. Di MR, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre' M, Nuciforo PG, Bensimon A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444(7119):638–42.View ArticleGoogle Scholar
  11. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ, Lowe SW. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol. 2002;22(10):3497–508.PubMedPubMed CentralView ArticleGoogle Scholar
  12. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593–602.PubMedView ArticleGoogle Scholar
  13. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, Finkel T. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem. 1999;274(12):7936–40.PubMedView ArticleGoogle Scholar
  14. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998;12(19):2997–3007.PubMedPubMed CentralView ArticleGoogle Scholar
  15. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 2007;21(1):43–8.PubMedPubMed CentralView ArticleGoogle Scholar
  16. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005;436(7051):642.PubMedView ArticleGoogle Scholar
  17. Chen QM, Prowse KR, Tu VC, Purdom S, Linskens MH. Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. Exp Cell Res. 2001;265(2):294–303.PubMedView ArticleGoogle Scholar
  18. Ben-Porath I, Weinberg RA. When cells get stressed: an integrative view of cellular senescence. J Clin Invest. 2004;113(1):8–13.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001;98(21):12072–7.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853–68.PubMedView ArticleGoogle Scholar
  21. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.PubMedPubMed CentralView ArticleGoogle Scholar
  22. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010;29(2):273–83.PubMedPubMed CentralView ArticleGoogle Scholar
  23. Xu T, Rubin GM. Analysis of genetic mosaics in developing and adult Drosophila tissues. Development. 1993;117(4):1223–37.PubMedGoogle Scholar
  24. Wu JS, Luo L. A protocol for mosaic analysis with a repressible cell marker (MARCM) in Drosophila. Nat Protoc. 2006;1(6):2583–9.PubMedView ArticleGoogle Scholar
  25. HAYFLICK L, MOORHEAD PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.PubMedView ArticleGoogle Scholar
  26. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol. 1999;19(3):2109–17.PubMedPubMed CentralView ArticleGoogle Scholar
  27. van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7501):439–46.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A, Kumar R, Jenkins RB, de Groen PC, Roche P, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet. 2004;36(7):744–9.PubMedView ArticleGoogle Scholar
  29. Meixner A, Karreth F, Kenner L, Penninger JM, Wagner EF. Jun and JunD-dependent functions in cell proliferation and stress response. Cell Death Differ. 2010;17(9):1409–19.PubMedView ArticleGoogle Scholar
  30. Andre T, Meuleman N, Stamatopoulos B, De BC, Pieters K, Bron D, Lagneaux L. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One. 2013;8(3):e59756.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363–7.PubMedPubMed CentralView ArticleGoogle Scholar
  32. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000;113(Pt 20):3613–22.PubMedGoogle Scholar
  33. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A. 1996;93(24):13742–7.PubMedPubMed CentralView ArticleGoogle Scholar
  34. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–7.PubMedView ArticleGoogle Scholar
  35. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817–825.1.PubMedView ArticleGoogle Scholar
  36. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366(6456):701–4.PubMedView ArticleGoogle Scholar
  37. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell. 2004;14(4):501–13.PubMedView ArticleGoogle Scholar
  38. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703–16.PubMedView ArticleGoogle Scholar
  39. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA, Myers MP, Lowe SW. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell. 2006;126(3):503–14.PubMedView ArticleGoogle Scholar
  40. Narita M. Cellular senescence and chromatin organisation. Br J Cancer. 2007;96(5):686–91.PubMedPubMed CentralView ArticleGoogle Scholar
  41. Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, Bartek J. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle. 2011;10(3):457–68.PubMedView ArticleGoogle Scholar
  42. Nakamura M, Ohsawa S, Igaki T. Mitochondrial defects trigger proliferation of neighbouring cells via a senescence-associated secretory phenotype in Drosophila. Nat Commun. 2014;5:5264.PubMedView ArticleGoogle Scholar
  43. Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature. 2012;490(7421):547–51.PubMedView ArticleGoogle Scholar
  44. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene. 2006;25(34):4647–62.PubMedView ArticleGoogle Scholar
  45. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer. 2002;1:9.PubMedPubMed CentralView ArticleGoogle Scholar
  46. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr Mol Med. 2007;7(1):121–31.PubMedView ArticleGoogle Scholar
  47. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res. 1978;22:190–274.PubMedView ArticleGoogle Scholar
  48. Tokarz P, Blasiak J. Role of mitochondria in carcinogenesis. Acta Biochim Pol. 2014;61(4):671–8.PubMedGoogle Scholar
  49. Harrison DA, McCoon PE, Binari R, Gilman M, Perrimon N. Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway. Genes Dev. 1998;12(20):3252–63.PubMedPubMed CentralView ArticleGoogle Scholar
  50. Llano E, Pendas AM, Aza-Blanc P, Kornberg TB, Lopez-Otin C. Dm1-MMP, a matrix metalloproteinase from Drosophila with a potential role in extracellular matrix remodeling during neural development. J Biol Chem. 2000;275(46):35978–85.PubMedView ArticleGoogle Scholar
  51. Chen JH, Hales CN, Ozanne SE. DNA damage, cellular senescence and organismal ageing: causal or correlative? Nucleic Acids Res. 2007;35(22):7417–28.PubMedPubMed CentralView ArticleGoogle Scholar
  52. Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci U S A. 1995;92(10):4337–41.PubMedPubMed CentralView ArticleGoogle Scholar
  53. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A. 1994;91(10):4130–4.PubMedPubMed CentralView ArticleGoogle Scholar
  54. Chen JH, Stoeber K, Kingsbury S, Ozanne SE, Williams GH, Hales CN. Loss of proliferative capacity and induction of senescence in oxidatively stressed human fibroblasts. J Biol Chem. 2004;279(47):49439–46.PubMedView ArticleGoogle Scholar
  55. Luo H, Yang A, Schulte BA, Wargovich MJ, Wang GY. Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage. PLoS One. 2013;8(3), e60065.PubMedPubMed CentralView ArticleGoogle Scholar
  56. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013;498(7452):109–12.PubMedView ArticleGoogle Scholar
  57. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420(1):25–7.PubMedView ArticleGoogle Scholar
  58. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006;21(3):307–15.PubMedPubMed CentralView ArticleGoogle Scholar
  59. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 1984;4(9):1689–94.PubMedPubMed CentralView ArticleGoogle Scholar
  60. Wang XQ, Gabrielli BG, Milligan A, Dickinson JL, Antalis TM, Ellem KA. Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay. Cancer Res. 1996;56(11):2510–4.PubMedGoogle Scholar
  61. Robles SJ, Adami GR. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 1998;16(9):1113–23.PubMedView ArticleGoogle Scholar
  62. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–12.PubMedView ArticleGoogle Scholar
  63. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994;76(6):1013–23.PubMedView ArticleGoogle Scholar
  64. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol. 2006;8(11):1291–7.PubMedView ArticleGoogle Scholar
  65. Brodsky MH, Weinert BT, Tsang G, Rong YS, McGinnis NM, Golic KG, Rio DC, Rubin GM. Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol. 2004;24(3):1219–31.PubMedPubMed CentralView ArticleGoogle Scholar
  66. Abdu U, Brodsky M, Schupbach T. Activation of a meiotic checkpoint during Drosophila oogenesis regulates the translation of Gurken through Chk2/Mnk. Curr Biol. 2002;12(19):1645–51.PubMedView ArticleGoogle Scholar
  67. Song YH. Drosophila melanogaster: a model for the study of DNA damage checkpoint response. Mol Cells. 2005;19(2):167–79.PubMedGoogle Scholar
  68. Akdemir F, Christich A, Sogame N, Chapo J, Abrams JM. p53 directs focused genomic responses in Drosophila. Oncogene. 2007;26(36):5184–93.PubMedView ArticleGoogle Scholar
  69. Brodsky MH, Nordstrom W, Tsang G, Kwan E, Rubin GM, Abrams JM. Drosophila p53 binds a damage response element at the reaper locus. Cell. 2000;101(1):103–13.PubMedView ArticleGoogle Scholar
  70. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, et al. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell. 2000;101(1):91–101.PubMedView ArticleGoogle Scholar
  71. Fan Y, Lee TV, Xu D, Chen Z, Lamblin AF, Steller H, Bergmann A. Dual roles of Drosophila p53 in cell death and cell differentiation. Cell Death Differ. 2010;17(6):912–21.PubMedView ArticleGoogle Scholar
  72. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B, Hainaut P, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011;18(12):1815–24.PubMedPubMed CentralView ArticleGoogle Scholar
  73. Mandal S, Freije WA, Guptan P, Banerjee U. Metabolic control of G1-S transition: cyclin E degradation by p53-induced activation of the ubiquitin-proteasome system. J Cell Biol. 2010;188(4):473–9.PubMedPubMed CentralView ArticleGoogle Scholar
  74. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 2001;413(6853):311–6.PubMedView ArticleGoogle Scholar
  75. Mandal S, Guptan P, Owusu-Ansah E, Banerjee U. Mitochondrial regulation of cell cycle progression during development as revealed by the tenured mutation in Drosophila. Dev Cell. 2005;9(6):843–54.PubMedView ArticleGoogle Scholar
  76. Yeh ES, Means AR. PIN1, the cell cycle and cancer. Nat Rev Cancer. 2007;7(5):381–8.PubMedView ArticleGoogle Scholar
  77. Kimura T, Gotoh M, Nakamura Y, Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 2003;94(5):431–6.PubMedView ArticleGoogle Scholar
  78. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 2004;432(7018):775–9.PubMedView ArticleGoogle Scholar
  79. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12(9):440–50.PubMedView ArticleGoogle Scholar
  80. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004;23(24):4802–12.PubMedPubMed CentralView ArticleGoogle Scholar
  81. Karpac J, Jasper H. Insulin and JNK: optimizing metabolic homeostasis and lifespan. Trends Endocrinol Metab. 2009;20(3):100–6.PubMedPubMed CentralView ArticleGoogle Scholar
  82. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol. 2005;7(3):278–85.PubMedView ArticleGoogle Scholar
  83. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev. 2006;70(4):1061–95.PubMedPubMed CentralView ArticleGoogle Scholar
  84. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002;277(33):29792–802.PubMedView ArticleGoogle Scholar
  85. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da CM, Brown C, Popov N, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133(6):1006–18.PubMedView ArticleGoogle Scholar
  86. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 2011;25(20):2125–36.PubMedPubMed CentralView ArticleGoogle Scholar
  87. Crescenzi E, Pacifico F, Lavorgna A, De PR, D'Aiuto E, Palumbo G, Formisano S, Leonardi A. NF-kappaB-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells. Oncogene. 2011;30(24):2707–17.PubMedView ArticleGoogle Scholar
  88. Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal. 2012;24(4):835–45.PubMedView ArticleGoogle Scholar
  89. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749–59.PubMedView ArticleGoogle Scholar
  90. Kozlowski M, Ladurner AG. ATM, MacroH2A.1, and SASP: the checks and balances of cellular senescence. Mol Cell. 2015;59(5):713–5.PubMedView ArticleGoogle Scholar
  91. Zhang H, Pan KH, Cohen SN. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci U S A. 2003;100(6):3251–6.PubMedPubMed CentralView ArticleGoogle Scholar
  92. Shah PP, Donahue G, Otte GL, Capell BC, Nelson DM, Cao K, Aggarwala V, Cruickshanks HA, Rai TS, McBryan T, et al. Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes Dev. 2013;27(16):1787–99.PubMedPubMed CentralView ArticleGoogle Scholar
  93. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693–706.PubMedPubMed CentralView ArticleGoogle Scholar
  94. Olivieri F, Rippo MR, Monsurro V, Salvioli S, Capri M, Procopio AD, Franceschi C. MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res Rev. 2013;12(4):1056–68.PubMedView ArticleGoogle Scholar
  95. Byun HJ, Hong IK, Kim E, Jin YJ, Jeoung DI, Hahn JH, Kim YM, Park SH, Lee H. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem. 2006;281(46):34833–47. 34831.PubMedView ArticleGoogle Scholar
  96. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253(1-2):269–85.PubMedView ArticleGoogle Scholar
  97. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res. 2006;66(22):10902–10.PubMedView ArticleGoogle Scholar
  98. Lin SJ, Lee IT, Chen YH, Lin FY, Sheu LM, Ku HH, Shiao MS, Chen JW, Chen YL. Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPS-treated human aortic smooth muscle cells. J Cell Biochem. 2007;100(2):372. 371-384.PubMedView ArticleGoogle Scholar
  99. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res. 2001;29(21):4361–72. 4362.PubMedPubMed CentralView ArticleGoogle Scholar
  100. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13(8):781. 797-792.PubMedGoogle Scholar
  101. Bunker BD, Nellimoottil TT, Boileau RM, Classen AK, Bilder D. The transcriptional response to tumorigenic polarity loss in Drosophila. Elife. 2015;4:1.View ArticleGoogle Scholar
  102. Page-McCaw A. Remodeling the model organism: matrix metalloproteinase functions in invertebrates. Semin Cell Dev Biol. 2008;19(1):14. 13-23.PubMedView ArticleGoogle Scholar
  103. Uhlirova M, Bohmann D. JNK- and Fos-regulated Mmp1 expression cooperates with Ras to induce invasive tumors in Drosophila. EMBO J. 2006;25(22):5294–304. 5292.PubMedPubMed CentralView ArticleGoogle Scholar
  104. An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpes virus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003;22(22):3371–85.PubMedView ArticleGoogle Scholar
  105. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A. 2008;105(21):7534. 7536-7539.PubMedPubMed CentralView ArticleGoogle Scholar
  106. Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011;25(6):634–45.PubMedPubMed CentralView ArticleGoogle Scholar
  107. Li LF, Ouyang B, Choukroun G, Matyal R, Mascarenhas M, Jafari B, Bonventre JV, Force T, Quinn DA. Stretch-induced IL-8 depends on c-Jun NH2-terminal and nuclear factor-kappaB-inducing kinases. Am J Physiol Lung Cell Mol Physiol. 2003;285(2):L464–75. 463.PubMedView ArticleGoogle Scholar
  108. Schmeck B, Moog K, van Laak V, Zahlten J, N'Guessan PD, Opitz B, Rosseau S, Suttorp N, Hippenstiel S. Streptococcus pneumoniae induced c-Jun-N-terminal kinase- and AP-1 -dependent IL-8 release by lung epithelial BEAS-2B cells. Respir Res. 2006;7:98.PubMedPubMed CentralView ArticleGoogle Scholar
  109. Yamana J, Santos L, Morand E. Enhanced induction of LPS-induced fibroblast MCP-1 by interferon-gamma: involvement of JNK and MAPK phosphatase-1. Cell Immunol. 2009;255(1-2):26. 26-32.PubMedView ArticleGoogle Scholar
  110. Wu J, Mei C, Vlassara H, Striker GE, Zheng F. Oxidative stress-induced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells. Am J Physiol Renal Physiol. 2009;297(6):F1622–31.PubMedPubMed CentralView ArticleGoogle Scholar
  111. Nomura J, Busso N, Ives A, Tsujimoto S, Tamura M, So A, Yamanaka Y. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS One. 2013;8(9):e75527.PubMedPubMed CentralView ArticleGoogle Scholar
  112. Jiang H, Patel PH, Kohlmaier A, Grenley MO, McEwen DG, Edgar BA. Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the Drosophila midgut. Cell. 2009;137(7):1343–55.PubMedPubMed CentralView ArticleGoogle Scholar
  113. Santabarbara-Ruiz P, Lopez-Santillan M, Martinez-Rodriguez I, Binagui-Casas A, Perez L, Milan M, Corominas M, Serras F. ROS-induced JNK and p38 signaling is required for unpaired cytokine activation during drosophila regeneration. PLoS Genet. 2015;11(10):e1005595–1005591.PubMedPubMed CentralView ArticleGoogle Scholar
  114. Badouel C, McNeill H. SnapShot: the hippo signaling pathway. Cell. 2011;145(3):484–484.e1. 481.PubMedView ArticleGoogle Scholar
  115. Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19(4):491–505.PubMedPubMed CentralView ArticleGoogle Scholar
  116. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61.PubMedPubMed CentralView ArticleGoogle Scholar
  117. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008;28(7):2426–36. 2426.PubMedPubMed CentralView ArticleGoogle Scholar
  118. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev. 2010;24(1):72–85. 73.PubMedPubMed CentralView ArticleGoogle Scholar
  119. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem. 2010;285(48):37159–69. 37158.PubMedPubMed CentralView ArticleGoogle Scholar
  120. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120–33. 1121.PubMedPubMed CentralView ArticleGoogle Scholar
  121. Staley BK, Irvine KD. Hippo signaling in Drosophila: recent advances and insights. Dev Dyn. 2012;241(1):3–15. 11.PubMedView ArticleGoogle Scholar
  122. Grusche FA, Richardson HE, Harvey KF. Upstream regulation of the hippo size control pathway. Curr Biol. 2010;20(13):R574–82.PubMedView ArticleGoogle Scholar
  123. Ren F, Zhang L, Jiang J. Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. Dev Biol. 2010;337(2):303–12. 314.PubMedView ArticleGoogle Scholar
  124. Oh H, Irvine KD. In vivo regulation of Yorkie phosphorylation and localization. Development. 2008;135(6):1081–8.PubMedPubMed CentralView ArticleGoogle Scholar
  125. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A. 2010;107(4):1437–42. 1431.PubMedPubMed CentralView ArticleGoogle Scholar
  126. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014;7(324):ra42–18.PubMedPubMed CentralView ArticleGoogle Scholar
  127. Kim T, Yang SJ, Hwang D, Song J, Kim M, Kyum KS, Kang K, Ahn J, Lee D, Kim MY, et al. A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat Commun. 2015;6:10186–1.PubMedPubMed CentralView ArticleGoogle Scholar
  128. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009;11(12):1444–50. 1442.PubMedPubMed CentralView ArticleGoogle Scholar
  129. Ren F, Wang B, Yue T, Yun EY, Ip YT, Jiang J. Hippo signaling regulates Drosophila intestine stem cell proliferation through multiple pathways. Proc Natl Acad Sci U S A. 2010;107(49):21064–9.PubMedPubMed CentralView ArticleGoogle Scholar
  130. Shaw RL, Kohlmaier A, Polesello C, Veelken C, Edgar BA, Tapon N. The Hippo pathway regulates intestinal stem cell proliferation during Drosophila adult midgut regeneration. Development. 2010;137(24):4147–58. 4141.PubMedPubMed CentralView ArticleGoogle Scholar
  131. Karpowicz P, Perez J, Perrimon N. The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration. Development. 2010;137(24):4135–45. 4138.PubMedPubMed CentralView ArticleGoogle Scholar
  132. Staley BK, Irvine KD. Warts and Yorkie mediate intestinal regeneration by influencing stem cell proliferation. Curr Biol. 2010;20(17):1580–7. 1582.PubMedPubMed CentralView ArticleGoogle Scholar
  133. Sun G, Irvine KD. Ajuba family proteins link JNK to Hippo signaling. Sci Signal. 2013;6(292):ra81.PubMedView ArticleGoogle Scholar
  134. Reddy BV, Irvine KD. Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell. 2013;24(5):459–71.PubMedPubMed CentralView ArticleGoogle Scholar
  135. Sun S, Reddy BV, Irvine KD. Localization of Hippo signalling complexes and Warts activation in vivo. Nat Commun. 2015;6:8402.PubMedPubMed CentralView ArticleGoogle Scholar
  136. Sun G, Irvine KD. Regulation of Hippo signaling by Jun kinase signaling during compensatory cell proliferation and regeneration, and in neoplastic tumors. Dev Biol. 2011;350(1):139–51.PubMedView ArticleGoogle Scholar
  137. Codelia VA, Sun G, Irvine KD. Regulation of YAP by mechanical strain through Jnk and Hippo signaling. Curr Biol. 2014;24(17):2012–7.PubMedPubMed CentralView ArticleGoogle Scholar
  138. Enomoto M, Kizawa D, Ohsawa S, Igaki T. JNK signaling is converted from anti- to pro-tumor pathway by Ras-mediated switch of Warts activity. Dev Biol. 2015;403(2):162–71.PubMedView ArticleGoogle Scholar
  139. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432(7015):307–15.PubMedView ArticleGoogle Scholar
  140. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57.PubMedPubMed CentralView ArticleGoogle Scholar
  141. Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. J Invest Dermatol. 1993;101(2):107–12.PubMedView ArticleGoogle Scholar
  142. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22(8):299–306.PubMedView ArticleGoogle Scholar
  143. Bergmann A, Agapite J, McCall K, Steller H. The Drosophila gene hid is a direct molecular target of Ras-dependent survival signaling. Cell. 1998;95(3):331–41.PubMedView ArticleGoogle Scholar
  144. Kurada P, White K. Ras promotes cell survival in Drosophila by downregulating hid expression. Cell. 1998;95(3):319–29.PubMedView ArticleGoogle Scholar
  145. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene. 2003;22(56):8999–9006.PubMedView ArticleGoogle Scholar
  146. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517–31.PubMedPubMed CentralView ArticleGoogle Scholar
  147. Hampel B, Wagner M, Teis D, Zwerschke W, Huber LA, Jansen-Durr P. Apoptosis resistance of senescent human fibroblasts is correlated with the absence of nuclear IGFBP-3. Aging Cell. 2005;4(6):325–30.PubMedView ArticleGoogle Scholar
  148. Ryu SJ, Oh YS, Park SC. Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts. Cell Death Differ. 2007;14(5):1020–8.PubMedGoogle Scholar
  149. Pasillas MP, Shields S, Reilly R, Strnadel J, Behl C, Park R, Yates III JR, Klemke R, Gonias SL, Coppinger JA. Proteomic analysis reveals a role for Bcl2-associated athanogene 3 and major vault protein in resistance to apoptosis in senescent cells by regulating ERK1/2 activation. Mol Cell Proteomics. 2015;14(1):1–14.PubMedView ArticleGoogle Scholar
  150. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 2014;15(11):1139–53.PubMedPubMed CentralView ArticleGoogle Scholar
  151. Rebbaa A, Zheng X, Chou PM, Mirkin BL. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene. 2003;22(18):2805–11.PubMedView ArticleGoogle Scholar


© The Author(s) 2016